WANA (Sep 21) – A team of Iranian researchers led by Fatemeh Bakhshandeh, Sadegh Sadeghzadeh, Fatemeh Keyvani, Leila Soleimani, and Mahla Poudineh, in collaboration with Canadian universities, has created an advanced wearable device called the “Aptalyzer.”

 

This innovative device uses microneedle patches and an electrochemical aptamer-based biosensor to enable continuous and precise monitoring of blood glucose and lactate levels through interstitial fluid.

 

The Aptalyzer is an integrated system that combines hydrogel-based microneedle patches with electrochemical aptamer sensors to monitor a wide range of biomarkers.

 

Aptamers, which are peptide or oligonucleotide molecules, bind specifically to target molecules, providing more accurate information compared to traditional methods.

 

This technology allows for continuous, painless monitoring of vital health indicators for up to one week.

 

Validation tests conducted on Type 1 diabetic mice and control mice demonstrated a strong correlation between the measurements obtained from the Aptalyzer and standard diagnostic methods.

 

This device effectively overcomes the limitations of enzyme-based diagnostics and enables simultaneous monitoring of multiple vital health indicators.

 

The painless sensor continuously collects data on blood glucose, lactate, and other vital markers, transmitting the information to mobile devices or other connected systems.

 

The Aptalyzer holds the potential to improve the management of chronic conditions like diabetes and could revolutionize the healthcare industry.